Journal of diabetes investigation
Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/CARD9/IRF5/NF-κB pathway.
Hao Chen, Sheng Xu, Bingrong Chen, Xishan Xiong, Jinrui Hu, Yuhong Wu, Tianrui Wang, Huishang Wang
Published: 202610.1111/jdi.70222
Abstract
BACKGROUND: Inflammation plays an essential role in the pathogenesis of diabetic nephropathy (DN). Linderalactone (LNL), as a natural sesquiterpene lactone, has been discovered to have anti-inflammatory activation. However, the effects of linderalact…
Preview only. Read the full abstract at the source